esophageal cancer
The company also recently published multiple new clinical validation studies to support its quest for reimbursement.
Lucid Diagnostics Raises $22M in Convertible Debt Refinancing
The cash raised brings the company’s total holdings to about $33 million, enough to see it through plans to gain reimbursement for its esophageal cancer test.
Previse Awarded $1.8M NIH Grant to Develop Esophageal Cancer Test
The Maryland-based firm said that the money will support the development and commercialization of a screening test for esophageal squamous cell carcinoma.
Lucid Diagnostics Partners With Front Line Mobile to Promote Esophageal Cancer Test
Working with the first responder medical care provider, Lucid is planning high-volume testing events among firefighters and other frontline workers with elevated risk.
Previse Completes Validation Study of Barrett's Esophagus Test, Sees Path to Guideline Inclusion
Premium
The epigenetic risk stratification test demonstrated the potential to decrease surveillance among some patients and increase it among others.
May 26, 2023
May 9, 2022
Castle Biosciences Q1 Revenues Grow 18 Percent
Feb 28, 2022